In this episode of TJ Talks, the guest is Professor Paolo Marchetti, a well-known expert in precision oncology in Italy, Full Professor of Medical Oncology at the University of Rome "La Sapienza", Scientific Director of IDI-IRCCS, President of the Foundation for Personalized Medicine and promoter of the Trial of Rome clinical study.

Precision oncology is a broad concept based on the study of the genome of tumour cells and Prof. Marchetti – interviewed by Prof. Giancarlo Pruneri -  highlights the clinical advantages of applying this path, without forgetting the factors that interfere with the possible response to a given drug: such factors include interactions, alterations of the microbiota, lifestyle and physical activity, making the scenario even more complex and fostering comparison among clinicians, molecular biologists, pathologists and geneticists on an ever-increasing number of heterogeneous data.

In precision oncology, the role of artificial intelligence in managing data from clinical trials is essential to understand potential mechanisms of drug resistance and synthesize the most appropriate and personalized knowledge for patient care.

In this episode of TJ Talks, the guest is Professor Paolo Marchetti, a well-known expert in precision oncology in Italy, Full Professor of Medical Oncology at the University of Rome "La Sapienza", Scientific Director of IDI-IRCCS, President of the Foundation for Personalized Medicine and promoter of the Trial of Rome clinical study.
Precision oncology is a broad concept based on the study of the genome of tumour cells and Prof. Marchetti &ndash; interviewed by Prof. Giancarlo Pruneri -&nbsp; highlights the clinical advantages of applying this path, without forgetting the factors that interfere with the possible response to a given drug: such factors include interactions, alterations of the microbiota, lifestyle and physical activity, making the scenario even more complex and fostering comparison among clinicians, molecular biologists, pathologists and geneticists on an ever-increasing number of heterogeneous data.
In precision oncology, the role of artificial intelligence in managing data from clinical trials is essential to understand potential mechanisms of drug resistance and synthesize the most appropriate and personalized knowledge for patient care.

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal.

The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care.

TJ Talks will be available from September on our website and on the best podcast platforms.

Follow us on Twitter and LinkedIn to always be updated on cancer research and clinical practice in oncology!

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal.
The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care.
TJ Talks will be available from September on our <a href="http://www.tumorijournal.org">website</a> and on the best podcast platforms.
Follow us on <a href="https://x.com/TumoriJ">Twitter</a> and <a href="https://www.linkedin.com/company/tumori-journal/">LinkedIn</a> to always be updated on cancer research and clinical practice in oncology!

TJ Talks

Conversations on trending topics in oncology hosted by the Editor-in-Chief of Tumori Journal, Prof. Giancarlo Pruneri.

Conversations on trending topics in oncology hosted by the Editor-in-Chief of Tumori Journal, Prof. Giancarlo Pruneri.

Advertisement